Full Press Release Details
DUBLIN , Oct. 22, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that it will report its third quarter 2013 financial results on Tuesday, November 5, 2013 , after the close of the financial markets. Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EST / 9:30 p.m. GMT to provide a business and financial update and discuss third quarter 2013 financial results.
Interested parties may access the live audio webcast via the Investors & Media section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com . Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary to listen to the webcast. A replay of the webcast will be archived on the website for one week.
Audio webcast/conference call: U.S. Dial-In Number: +1 800 591 6942 International Dial-In Number: +1 617 614 4909 Passcode: 48257479
A replay of the conference call will be available through November 12, 2013 and accessible through one of the following telephone numbers and entering the passcode:
Replay U.S. Dial-In Number: +1 888 286 8010 Replay International Dial-In Number: +1 617 801 6888 Passcode: 18933289
About Jazz Pharmaceuticals Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing innovative products that address unmet medical needs. The company has a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry. The company's U.S. marketed products in these areas include: Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi), Prialt® (ziconotide) intrathecal infusion, FazaClo® (clozapine, USP) HD and FazaClo LD. Outside of the U.S., Jazz Pharmaceuticals also has a number of products marketed by its EUSA Pharma division. For further information, see www.jazzpharmaceuticals.com .
SOURCE Jazz Pharmaceuticals plc